The prevalence of type 2 diabetes across the world has been described as a global pandemic. Despite the introduction of new agents, efforts for better management of diabetes are disappointing and the control of blood glucose level remains unsatisfactory. When antidiabetic therapy is initiated, it is now recommended that the selection of agents should be directed towards both fasting as well as postprandial hyperglycaemia. Material and method: This study was a post marketing surveillance (PMS) non-randomized, open, non-comparative, mono centric study. The drug administered was a fixed dose combination of Voglibose 0.2mg, Glimepiride 1/2mg and Metformin 500mg SR, 20 type 2 diabetic patients were given fixed dose combination twice daily with major meals for 3 months. Observation: Baseline value was recorded for glycated haemoglobin (HbA1c), fasting blood glucose and post prandial blood glucose level. There was significant decrease in glycated haemoglobin value (8.86 __ampersandsignplusmn; 0.7111 gm/dl vs. 8.0 __ampersandsignplusmn; 0.66 gm/dl), fasting (137__ampersandsignplusmn;17.64 mg/dl vs. 116.8 __ampersandsignplusmn; 6.129 mg/dl, P __ampersandsignlt; 0.0001) and post prandial blood glucose level ((237.8 __ampersandsignplusmn; 59.22 mg/dl vs.173.4 __ampersandsignplusmn; 27.6 P __ampersandsignlt; 0.0004) after 3 months of treatment. The combination was found to be effective in controlling both fasting and post prandial glucose level and was well tolerated. Investigator commented that the use of triple drug combination is a good option in the management of type 2 diabetes which controls both fasting as well as post prandial blood glucose. Conclusion: The triple drug fixed dose combination of Voglibose, Glimepiride and Metformin significantly decreased the HbA1c value, fasting plasma glucose level and post prandial glucose level at the end of the treatment.